Market size, growth to 2033 and clinical trials, side by side.
Germany is the bigger HIV Drugs market: $1.1 Bn against $780 Mn in 2023, about 1.4 times as large.
Germany grows faster: 4% a year, against 3.8%.
Clinical research: 25 active trials in the UK, 15 in Germany.
| Measure | ||
|---|---|---|
| Market size, 2023 | $780 Mn | $1.1 Bn |
| Market size, 2033 projected | $1.1 Bn | $1.6 Bn |
| Growth a year (CAGR) | 3.8% | 4% |
| Money added, 2023–2033 | $353 Mn | $527 Mn |
| Share of the world market | 2.6% | 3.7% |
| Size rank of 24 countries | #7 | #5 |
| Market per person, 2023 | $11 | $13 |
| Active clinical trials | 25 | 15 |
| New HIV infections people (WHO) | 2,100 2024 | 2,300 2024 |
| Full report | UK report | Germany report |
UK Germany · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Germany is the bigger HIV Drugs market: $1.1 Bn against $780 Mn in 2023, about 1.4 times as large.
Germany grows faster: 4% a year, against 3.8%.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.